Reduction of Coronavirus Burden With Mass Azithromycin Distribution
Thuy Doan, Armin Hinterwirth, Ahmed M. Arzika, Lee Worden, Cindi Chen, Lina Zhong, Catherine E. Oldenburg, Jeremy D. Keenan, Thomas M. Lietman
Abstract
We evaluated the potential antiviral effects of azithromycin on the nasopharyngeal virome of Nigerien children who had received multiple rounds of mass drug administration. We found that the respiratory burden of non-severe acute respiratory syndrome coronaviruses was decreased with azithromycin distributions. Clinical Trials Registration. NCT02047981.
Topics & Concepts
AzithromycinMedicineCoronavirus disease 2019 (COVID-19)Respiratory systemSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakCoronavirusInternal medicineVirologyMicrobiologyAntibioticsOutbreakBiologyDiseaseInfectious disease (medical specialty)Pneumonia and Respiratory InfectionsRespiratory viral infections researchInfluenza Virus Research Studies